source
- STAT+: A German biotech has big ambitions in cancer. Now it needs to get a medicine approvedAfter a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.STAT · 50m ago↗ source
- Opinion: How knocking on doors can help beat measles — again“As measles outbreaks spread in the U.S., it may be time to learn how other countries get their outbreaks under control,” writes Raj Panjabi.STAT · 50m ago↗ source
- Opinion: Replication is necessary even if scientists do everything right“Committing a Type 1 error does not reflect poorly on the quality of the science done,” writes Mark Louie F. RamosSTAT · 50m ago↗ source